521 related articles for article (PubMed ID: 29410094)
1. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals.
Papst L; Beović B; Pulcini C; Durante-Mangoni E; Rodríguez-Baño J; Kaye KS; Daikos GL; Raka L; Paul M;
Clin Microbiol Infect; 2018 Oct; 24(10):1070-1076. PubMed ID: 29410094
[TBL] [Abstract][Full Text] [Related]
2. Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014.
Yang P; Chen Y; Jiang S; Shen P; Lu X; Xiao Y
Antimicrob Resist Infect Control; 2018; 7():137. PubMed ID: 30479750
[TBL] [Abstract][Full Text] [Related]
3. Effects of various antimicrobial stewardship programs on antimicrobial usage and resistance among common gram-negative bacilli causing health care-associated infections: A multicenter comparison.
Lai CC; Shi ZY; Chen YH; Wang FD
J Microbiol Immunol Infect; 2016 Feb; 49(1):74-82. PubMed ID: 26586483
[TBL] [Abstract][Full Text] [Related]
4. Molecular epidemiology of carbapenem resistant gram-negative bacilli from infected pediatric population in tertiary - care hospitals in Medellín, Colombia: an increasing problem.
Vanegas JM; Parra OL; Jiménez JN
BMC Infect Dis; 2016 Sep; 16(1):463. PubMed ID: 27585707
[TBL] [Abstract][Full Text] [Related]
5. [Surveillance of resistance in the intensive care units using a cumulative antibiogram].
Yürüyen C; Daldaban Dinçer Ş; Yanılmaz Ö; Boz ES; Aksaray S
Mikrobiyol Bul; 2018 Oct; 52(4):329-339. PubMed ID: 30522419
[TBL] [Abstract][Full Text] [Related]
6. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
[TBL] [Abstract][Full Text] [Related]
7. Treatment and Outcome of Carbapenem-Resistant Gram-Negative Bacilli Blood-Stream Infections in a Tertiary Care Hospital.
Shah PG; Shah SR
J Assoc Physicians India; 2015 Jul; 63(7):14-8. PubMed ID: 26731822
[TBL] [Abstract][Full Text] [Related]
8. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
Kaye KS; Pogue JM
Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.
Crusio R; Rao S; Changawala N; Paul V; Tiu C; van Ginkel J; Chapnick E; Kupfer Y
Scand J Infect Dis; 2014 Jan; 46(1):1-8. PubMed ID: 24206450
[TBL] [Abstract][Full Text] [Related]
10. Clinical management of severe infections caused by carbapenem-resistant gram-negative bacteria: a worldwide cross-sectional survey addressing the use of antibiotic combinations.
Carrara E; Savoldi A; Piddock LJV; Franceschi F; Ellis S; Sharland M; Brink AJ; Harris PNA; Levy-Hara G; Rohit A; Tsioutis C; Zayyad H; Giske C; Chiamenti M; Bragantini D; Righi E; Gorska A; Tacconelli E
Clin Microbiol Infect; 2022 Jan; 28(1):66-72. PubMed ID: 33975010
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Scudeller L; Righi E; Chiamenti M; Bragantini D; Menchinelli G; Cattaneo P; Giske CG; Lodise T; Sanguinetti M; Piddock LJV; Franceschi F; Ellis S; Carrara E; Savoldi A; Tacconelli E
Int J Antimicrob Agents; 2021 May; 57(5):106344. PubMed ID: 33857539
[TBL] [Abstract][Full Text] [Related]
12. Occurrence and characterization of carbapenem-resistant Gram-negative bacilli: A collaborative study of antibiotic-resistant bacteria between Indonesia and Japan.
Kuntaman K; Shigemura K; Osawa K; Kitagawa K; Sato K; Yamada N; Nishimoto K; Yamamichi F; Rahardjo D; Hadi U; Mertaniasih NM; Kinoshita S; Fujisawa M; Shirakawa T
Int J Urol; 2018 Nov; 25(11):966-972. PubMed ID: 30253445
[TBL] [Abstract][Full Text] [Related]
13. International guidelines for the treatment of carbapenem-resistant Gram-negative Bacilli infections: A comparison and evaluation.
Wang C; Bai C; Chen K; Du Q; Cheng S; Zeng X; Wang Y; Dong Y
Int J Antimicrob Agents; 2024 May; 63(5):107120. PubMed ID: 38417705
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic consumption versus the prevalence of carbapenem-resistant Gram-negative bacteria at a tertiary hospital in China from 2011 to 2017.
Zhang D; Hu S; Sun J; Zhang L; Dong H; Feng W; Lei J; Dong Y
J Infect Public Health; 2019; 12(2):195-199. PubMed ID: 30385238
[TBL] [Abstract][Full Text] [Related]
15. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
[TBL] [Abstract][Full Text] [Related]
16. The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies.
Savoldi A; Carrara E; Piddock LJV; Franceschi F; Ellis S; Chiamenti M; Bragantini D; Righi E; Tacconelli E
BMC Infect Dis; 2021 Jun; 21(1):545. PubMed ID: 34107899
[TBL] [Abstract][Full Text] [Related]
17. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Ardebili A; Izanloo A; Rastegar M
Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
[TBL] [Abstract][Full Text] [Related]
18. Association between the rate of fluoroquinolones-resistant gram-negative bacteria and antibiotic consumption from China based on 145 tertiary hospitals data in 2014.
Yang P; Chen Y; Jiang S; Shen P; Lu X; Xiao Y
BMC Infect Dis; 2020 Apr; 20(1):269. PubMed ID: 32264851
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization and risk factors for carbapenem-resistant Gram-negative bacilli colonization in children: emergence of NDM-producing Acinetobacter baumannii in a newborn intensive care unit in Turkey.
Karaaslan A; Soysal A; Altinkanat Gelmez G; Kepenekli Kadayifci E; Söyletir G; Bakir M
J Hosp Infect; 2016 Jan; 92(1):67-72. PubMed ID: 26601601
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
